Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 6/20 | 0.42 |
| ▸ | PFKFB4 | Q16877 | 6/20 | 0.42 |
| ▸ | CMA1 | P23946 | 6/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472162 | 0.88 | NPSR1 (0.45) | NPSR1L3MBTL1HTR6PFKFB3PFKFB4 | |
| SCHEMBL2226181 | 0.81 | NPSR1 (0.60) | NPSR1L3MBTL1PFKFB3PFKFB4CMA1 | |
| Hydrochloric Acid SCHEMBL6712744 | 0.80 | NPSR1 (0.59) | NPSR1L3MBTL1PFKFB3PFKFB4CMA1 | |
| SCHEMBL3690124 | 0.79 | L3MBTL1 (0.45) | NPSR1L3MBTL1HTR6PFKFB3PFKFB4 | |
| SCHEMBL3687045 | 0.78 | NPSR1 (0.44) | NPSR1L3MBTL1PFKFB3PFKFB4CMA1 | |
| SCHEMBL3692731 | 0.75 | NPSR1 (0.41) | NPSR1L3MBTL1PFKFB3PFKFB4CMA1 | |
| SCHEMBL3947527 | 0.73 | HTR6 (0.45) | NPSR1L3MBTL1HTR6PFKFB3PFKFB4 | |
| SCHEMBL4658351 | 0.72 | NPSR1 (0.47) | NPSR1L3MBTL1HTR6PFKFB3PFKFB4 | |
| SCHEMBL13696908 | 0.70 | NPSR1 (0.62) | NPSR1L3MBTL1HTR6PFKFB3PFKFB4 | |
| SCHEMBL337593 | 0.70 | NPSR1 (0.62) | NPSR1L3MBTL1PFKFB3PFKFB4CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450806-B1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB PUBL (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1450806-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166663-A1 | Use | BIOVITRUM AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003039547-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166663-A1 | Use | SULT2A1, SULT1A1, SLC5A1 | NPSR1 76/4885L3MBTL1 3160/4885HTR6 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.